Pfizer Inc. (PFE) Shares Sold by Old Mutual Global Investors UK Ltd.

Old Mutual Global Investors UK Ltd. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 30.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 14,579 shares of the biopharmaceutical company’s stock after selling 6,302 shares during the period. Old Mutual Global Investors UK Ltd.’s holdings in Pfizer were worth $520,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. HL Financial Services LLC raised its stake in shares of Pfizer by 1.1% during the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after buying an additional 35,744 shares during the last quarter. Hartford Financial Management Inc. raised its stake in shares of Pfizer by 10.8% during the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 835 shares during the last quarter. Cadence Bank NA raised its stake in shares of Pfizer by 1.4% during the 2nd quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock worth $3,358,000 after buying an additional 1,428 shares during the last quarter. Majedie Asset Management Ltd raised its stake in shares of Pfizer by 7.9% during the 2nd quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock worth $11,320,000 after buying an additional 24,531 shares during the last quarter. Finally, Stanley Laman Group Ltd. raised its stake in shares of Pfizer by 373.7% during the 2nd quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock worth $3,839,000 after buying an additional 90,160 shares during the last quarter. Institutional investors own 69.74% of the company’s stock.

In other news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,450 shares of company stock valued at $1,065,220. Corporate insiders own 0.06% of the company’s stock.

Pfizer Inc. (NYSE PFE) opened at $36.54 on Friday. Pfizer Inc. has a one year low of $30.90 and a one year high of $37.35. The firm has a market cap of $217,800.00, a PE ratio of 22.42, a P/E/G ratio of 2.44 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the prior year, the company posted $0.61 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

Pfizer declared that its board has approved a share buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is currently 78.53%.

Several research analysts have recently issued reports on the company. Morgan Stanley set a $41.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, January 8th. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price for the company. in a research note on Monday. Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $38.83.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.thestockobserver.com/2018/01/14/pfizer-inc-pfe-shares-sold-by-old-mutual-global-investors-uk-ltd.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply